Trials / Completed
CompletedNCT00754819
Targeting Inflammation in Acute Coronary Syndrome Using Colchicine
Colchicine Compared With Placebo to Reduce Hs-CRP in Patients With Acute Coronary Syndromes- Targeting Inflammation in Atherosclerosis Trial
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Hamilton Health Sciences Corporation · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of colchicine on high sensitivity C-reactive protein (hs-CRP), a blood marker to measure inflammation, in patients with acute coronary syndromes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Colchicine | 1mg once daily |
| DRUG | Placebo | 1 capsule daily |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2008-09-18
- Last updated
- 2009-10-08
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00754819. Inclusion in this directory is not an endorsement.